{
    "pmid": "41385967",
    "title": "4-Phenylbutyrate rescues neurobehavioral phenotypes in SLC6A1-related encephalopathy.",
    "abstract": "Developmental and epileptic encephalopathies (DEEs) caused by pathogenic variants in SLC6A1, encoding Î³-aminobutyric acid (GABA) transporter 1 (GAT-1), present with seizures and severe comorbidities including cognitive impairment, developmental delay, motor difficulties, and social deficits. Current therapies focus on seizure reduction but do not address the disabling neurobehavioral symptoms. We previously showed that 4-phenylbutyrate (PBA), known as a chemical chaperone and histone deacetylase inhibitor, restores GAT-1 function and reduces seizures in both mouse models and humans with SLC6A1 variants. Here, we tested whether PBA can improve neurobehavioral deficits in the Slc6a1",
    "disease": "epilepsy",
    "clean_text": "phenylbutyrate rescues neurobehavioral phenotypes in slc a related encephalopathy developmental and epileptic encephalopathies dees caused by pathogenic variants in slc a encoding aminobutyric acid gaba transporter gat present with seizures and severe comorbidities including cognitive impairment developmental delay motor difficulties and social deficits current therapies focus on seizure reduction but do not address the disabling neurobehavioral symptoms we previously showed that phenylbutyrate pba known as a chemical chaperone and histone deacetylase inhibitor restores gat function and reduces seizures in both mouse models and humans with slc a variants here we tested whether pba can improve neurobehavioral deficits in the slc a"
}